ADCT furnishes Q2 2025 results press release via 8-K

Rhea-AI Filing Summary

ADC Therapeutics SA filed an 8‑K and furnished a press release announcing financial results for the quarter ended September 30, 2025.

The release is included as Exhibit 99.1 and, as stated under Item 2.02, the information is furnished and not deemed filed under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000177191000017719102025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 10, 2025

ADC Therapeutics SA

(Exact Name of Registrant as Specified in Its Charter)

Switzerland (State or Other Jurisdiction of Incorporation)			001-39071 (Commission File Number)						N/A (IRS Employer Identification Number)
Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of Principal Executive Offices) (Zip Code)						+41 21 653 02 00 (Registrant’s Telephone Number)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Each Class			Trading Symbol			Name of Each Exchange on Which Registered
Common Shares, par value CHF 0.08 per share			ADCT			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 C.F.R. §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 10, 2025, ADC Therapeutics SA (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information contained in this Item 2.02 and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number			Description
99.1			Press Release dated November 10, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ADC Therapeutics SA
Date: November 10, 2025
			By:			/s/ Jose Carmona
			Name:			Jose Carmona
			Title:			Chief Financial Officer

FAQ

What did ADC Therapeutics (ADCT) disclose in this 8-K?

The company furnished a press release announcing financial results for the quarter ended September 30, 2025.

Which period do the results cover for ADCT?

The second quarter ended September 30, 2025.

Where can I find the ADCT results press release?

It is attached as Exhibit 99.1 to the 8‑K.

Is the information in Item 2.02 considered filed?

No. It is expressly stated as furnished and not deemed filed under the Exchange Act.

What is the ADCT trading symbol and exchange?

The trading symbol is ADCT on the New York Stock Exchange.

Who signed the 8-K for ADCT?

It was signed by Jose Carmona, Chief Financial Officer.